Financial Performance - For the fiscal year ending December 31, 2025, the total revenue from sales of goods and services was HKD 71,948,000, a decrease of 21.8% compared to HKD 91,932,000 in 2024[4] - The gross profit for 2025 was HKD 22,954,000, down from HKD 29,436,000 in 2024, reflecting a gross margin decline[4] - The company reported a profit from continuing operations of HKD 47,563,000 for 2025, a significant recovery from a loss of HKD 78,832,000 in 2024[4] - Total comprehensive income for the year was HKD 58,282,000, compared to a loss of HKD 87,499,000 in the previous year[6] - The basic earnings per share from continuing operations improved to HKD 0.41 from a loss of HKD 2.81 in 2024[5] - The group reported a pre-tax profit of HKD 26,799,000 for 2025, a turnaround from a loss of HKD 88,107,000 in 2024[31] - Basic and diluted earnings per share from continuing and discontinued operations for 2025 were HKD 0.95, compared to a loss of HKD 3.14 in 2024[31] Revenue Breakdown - Total revenue for 2025 is HKD 71,948,000, a decrease of 21.7% from HKD 91,932,000 in 2024[24] - Revenue from the packaging products segment for 2025 is HKD 62,277,000, down 17.9% from HKD 75,847,000 in 2024[24] - Revenue from the Rhaetian algae products segment for 2025 is HKD 9,671,000, a decline of 39.9% compared to HKD 16,085,000 in 2024[24] - The financial investment segment reported a loss of HKD 4,978,000 in 2025, compared to a profit of HKD 7,666,000 in 2024[21] Asset and Liability Management - Non-current assets decreased to HKD 521,359,000 in 2025 from HKD 376,266,000 in 2024, primarily due to changes in financial assets[7] - Current liabilities increased to HKD 591,449,000 in 2025 from HKD 557,983,000 in 2024, indicating a rise in financial obligations[8] - The company’s net asset value improved to HKD 27,391,000 in 2025 from a negative value of HKD 40,642,000 in 2024[8] - As of December 31, 2025, the group's net current liabilities amounted to approximately HKD 493,104,000, with total current liabilities including bank and other borrowings at approximately HKD 534,345,000[10] - The group's cash and cash equivalents were only about HKD 5,063,000 as of December 31, 2025, indicating significant liquidity concerns[10] Financing and Capital Structure - The group has outstanding other borrowings of approximately HKD 176,144,000 that are due for immediate repayment[10] - The group is negotiating with financial institutions to obtain new financing to repay existing loans and/or secure additional working capital[10] - The group is actively seeking additional financing sources, including potential loans from directors, to maintain relationships with existing lenders and avoid immediate repayment demands[10] - The board believes that the financial situation will improve with the implementation of these measures, allowing the group to meet its financial obligations for at least the next twelve months[11] Operational Changes - The company has ceased operations in its packaging solutions business, which was previously reported as a separate segment[9] - The company is engaged in the production and sale of packaging products, securities investment, and lending activities, indicating a focus on core business areas[9] Cost Management - Cost control measures are being implemented to reduce sales costs, administrative expenses, and capital expenditures, aiming to increase internal cash generation and operating cash flow[13] - The group may continue to seek other methods to increase working capital, such as selling non-listed investments classified at fair value[13] Employee and Corporate Governance - As of December 31, 2025, the group employed approximately 296 full-time employees in Hong Kong and China, a decrease from 485 full-time employees in 2024[95] - The company has complied with all applicable corporate governance code provisions, except for the absence of the chairman at the annual general meeting due to other business commitments[113] - The audit committee consists of three independent non-executive directors, ensuring compliance with applicable accounting standards and regulations for the financial statements for the year ending December 31, 2025[117] Stock Options and Shareholder Information - The 2022 stock option plan was approved on June 2, 2022, and will terminate on June 13, 2025, with no further options to be granted under the 2022 plan[57] - The total number of stock options granted in the year includes 47 million at an exercise price of 0.40 HKD, 68.9 million at 0.60 HKD, and 14.3 million at 1.34 HKD[60] - The company has granted stock options to three advisors, totaling 50 million options, aimed at enhancing business insights and potential investor connections[61] - The group recognized an expense of approximately HKD 1,286,000 for share-based payments in the year ended December 31, 2025, down from HKD 3,639,000 in 2024[65] Business Discontinuation - The group reported a loss of HKD 9,140,000 from the discontinued QR code business for the year ended 2025, compared to a loss of HKD 9,208,000 in 2024[68] - The group has terminated its involvement in the QR code business following the completion of the sale on August 29, 2025[67] Investment Strategy - The investment policy mandates that the total book value of financial investments must not exceed 60% of the group's total assets, ensuring a significant portion of assets is reserved for core operational needs, working capital, debt repayment, and emergency requirements[109] - The company aims to achieve an average annualized return of approximately 15% for each investment, with regular reviews of investment performance and market conditions[110] - The investment portfolio is concentrated in the financial services sector, which includes securities trading, brokerage, lending, and asset management, with expectations of recovery based on improved macroeconomic conditions[112]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Touyun Biotech Group Limited 透 雲 生 物 科 技 集 團 有 限 公 司 （於百慕達註冊成立的有限公司） （股份代號： 1332） 正面盈利預告 本公告乃由透雲生物科技集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 （「董事」）會（「董事會」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規 則」）第13.09條以及香港法例第571章證券及期貨條例第XIVA部的內幕消息條文（定義見 上市規則）而作出。 董事會謹此知會本公司股東（「股東」）及潛在投資者，根據對本集團截至2025年12月31日 止年度（「本年度」）未經審核綜合管理賬目的初步評估，本集團預期將錄得本公司本年度 溢利（「溢利」）不少於55,000,000港元，而本公司於截至2024年12月31日止年度錄得虧損 （「虧損」）約79,000,000港元。由虧轉盈主要歸因於本集團就非上市及上 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 香港，2026年3月13日 於本公告日期，董事會包括下列董事： 執行董事 王亮先生 （主席） 杜東先生 田宇澤女士 Touyun Biotech Group Limited 非執行董事 陳輝先生 張樂樂先生 透 雲 生 物 科 技 集 團 有 限 公 司 （於百慕達註冊成立的有限公司） （股份代號： 1332） 董事會召開日期 透雲生物科技集團有限公司（「本公司」）董事會（「董事會」）宣布，本公司將於2026年3月 27日（星期五）舉行董事會會議，藉以（其中包括）批准刊發本公司及其附屬公司截至2025 年12月31日止年度的全年業績公告，以及考慮派發末期股息。 承董事會命 透雲生物科技集團有限公司 主席 王亮 獨立非執行董事 張榮平先生 夏其才先生 杜成泉先生 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 透雲生物科技集團有限公司 呈交日期: 2026年3月2日 FF301 第 1 頁 共 10 頁 v 1.2.0 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01332 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 2,805,952,149 | | 0 | | 2,805,952,149 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 2,805,952,149 | | 0 | | 2,805,952,149 | 足夠公眾持 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 透雲生物科技集團有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01332 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 12,500,000,000 | HKD | | 0.04 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 12,500,000,000 | HKD | | 0.04 | HKD | | 500,000,000 | ...

Investment Policy - The investment policy limits the total book value of financial investments to no more than 60% of the group's total assets, ensuring a significant portion of assets is reserved for core operational needs and liquidity [5]. - At least 30% of the investment portfolio's value must be allocated to highly liquid assets, primarily listed company stocks, to maintain financial flexibility [5]. - The group prohibits investments in high-risk or speculative products, ensuring a focus on sustainable and transparent investment opportunities [5]. Investment Strategy - The group aims for an average annualized return of approximately 15% on each investment, with a strict re-evaluation process triggered if the fair value of an investment declines by 50% from its initial cost [6]. - The investment strategy is dynamic and subject to regular review to reflect changing market conditions and regulatory requirements [7]. - The management will consider partial or full liquidation of investments to maximize shareholder value when performance targets are met or risks are managed [8]. Market Outlook - As of December 31, 2024, the group's investment portfolio is concentrated in the financial services sector, which is expected to provide attractive risk-adjusted returns and support asset diversification [8]. - The management anticipates a recovery in the financial services industry driven by improved macroeconomic conditions, increased capital market activity, and stable investor sentiment [8]. Governance and Oversight - The board retains final approval authority for major investments and regularly reviews compliance with policy limits and overall strategy [7]. - The group emphasizes a disciplined approach to capital allocation, ensuring alignment with long-term shareholder value enhancement [4].

Group 1 - The core viewpoint of the article highlights the recent stock transfer of Tuo Yun Biotechnology (01332) from Mingji Securities to China Merchants Yonglong Bank, with a market value of HKD 26.8185 million, representing 9.02% of the company [1] - Tuo Yun Biotechnology reported a revenue of HKD 36.581 million for the six months ending June 30, 2025, reflecting a year-on-year decrease of 20.82% [1] - The company achieved a profit attributable to shareholders of HKD 11.243 million, a significant turnaround from a loss of HKD 47.969 million in the same period last year, with earnings per share of HKD 0.004 [1]

Group 1 - The core point of the article highlights the transfer of shares of Tuo Yun Biotechnology (01332) from Mingji Securities to China Merchants Yonglong Bank, with a market value of HKD 26.8185 million, accounting for 9.02% of the total shares [1] - Tuo Yun Biotechnology reported a revenue of HKD 36.581 million for the six months ending June 30, 2025, representing a year-on-year decrease of 20.82% [1] - The company recorded a profit attributable to shareholders of HKD 11.243 million, a significant turnaround from a loss of HKD 47.969 million in the same period last year, with earnings per share of HKD 0.004 [1]

Group 1 - Sanhua Intelligent Control (02050) saw a decline of over 3.4% after announcing a share reduction plan involving the actual controller and several directors, with a total of up to approximately 10.2 million A-shares to be sold between February 24, 2026, and May 23, 2026 [1] - Tuo Yun Biotechnology (01332) experienced a significant drop of over 60%, nearly erasing gains since October 2022, following stock movements involving major shareholders [1] - Zhongwei New Materials (02579) increased by over 5% as the company announced securing 5-6 billion wet tons of nickel ore resources and establishing four nickel raw material industrial bases in Indonesia [1] Group 2 - InnoCare Pharma (03696) rose over 6%, reaching a new high of 62.9 HKD, after receiving FDA approval for its oral NLRP3 inhibitor ISM8969 for Parkinson's disease treatment [2] - Solar stocks surged, with Kaisa New Energy (01108) up 17.85% and other companies like Fuyao Glass (06865) and Xinyi Solar (00968) also showing significant gains, driven by a report indicating a new phase in commercial space deployment [2] - Jiangnan Buyi (03306) fell nearly 7% after announcing a placement of 14.535 million shares at a discount to the market price [2] Group 3 - Lithium stocks rose, with Ganfeng Lithium (01772) up 5.22% and Tianqi Lithium (09696) up 2.88%, following a report of a significant increase in lithium carbonate contract prices [3] - Rongchang Bio (09995) increased nearly 2% after UBS expressed a positive outlook on its collaboration with AbbVie, which includes substantial milestone payments [4] - DCH Holdings (00179) fell nearly 7% as it reported a slight decline in revenue for the nine months ending December 31, 2025 [4] Group 4 - Gold stocks rebounded, with Chifeng Jilong Gold Mining (06693) up 6.99% and others also showing gains, as spot gold prices reached a new high of over $4,960 per ounce [4] - Bitgo Holdings (BTGO.US) debuted on the US stock market, rising 2.72% as a leading cryptocurrency custody provider [5] - Rare earth stocks surged, with USA Rare Earth (USAR.US) up 17.49% after announcing partnerships to advance its Round Top project [5] Group 5 - The Nasdaq Golden Dragon China Index opened up 1.6%, with major Chinese stocks like Li Auto (LI.US) and Alibaba (BABA.US) showing gains, supported by comments from the People's Bank of China regarding potential monetary easing [6] - Abbott (ABT.US) fell 10.04% after reporting lower-than-expected sales for Q4 2025, despite a year-over-year increase in adjusted EPS [7] - Alibaba (BABA.US) rose 5.05% as it plans to list its semiconductor division, benefiting from investor interest in competing with Nvidia [7]

Core Viewpoint - Tuo Yun Biotechnology (01332) experienced a significant drop of over 60% in its stock price, nearly erasing gains made since late October of the previous year [1] Group 1: Stock Performance - As of the latest update, Tuo Yun's stock price fell by 60%, trading at HKD 0.104, with a trading volume of HKD 85.13 million [1] - The stock's decline is attributed to shareholder activities, including the deposit of shares into Mingji Securities, valued at HKD 36.58 million, representing 5.85% of the total [1] - Additionally, a transfer of shares from Wutong Securities to KGI Securities Asia occurred, with a value of HKD 35.35 million, accounting for 5.04% [1] Group 2: Company Overview - Tuo Yun Biotechnology's primary business includes providing QR codes and solutions for product packaging, manufacturing and selling packaging products, securities investment and trading, lending, and producing and selling Rhizoclonium, microalgae, and related products [1] - For the mid-year results of 2025, the company reported revenue of HKD 36.58 million from goods and services, reflecting a year-on-year decrease of 20.82% [1] - The company achieved a profit attributable to shareholders of HKD 11.24 million, marking a turnaround from a loss to profitability year-on-year [1]